Mayne Pharma Group Ltd (MYX) - Total Assets
Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) holds total assets worth AU$1.01 Billion AUD (≈ $717.90 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Mayne Pharma Group Ltd for net asset value and shareholders' equity analysis.
Mayne Pharma Group Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Mayne Pharma Group Ltd's total assets have evolved over time, based on quarterly financial data.
Mayne Pharma Group Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Mayne Pharma Group Ltd's total assets of AU$1.01 Billion consist of 34.8% current assets and 65.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 5.9% |
| Accounts Receivable | AU$164.62 Million | 16.2% |
| Inventory | AU$50.56 Million | 5.0% |
| Property, Plant & Equipment | AU$58.87 Million | 5.8% |
| Intangible Assets | AU$542.11 Million | 53.4% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Mayne Pharma Group Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mayne Pharma Group Ltd (MYX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mayne Pharma Group Ltd's current assets represent 34.8% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, down from 100.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 53.4% of total assets.
Mayne Pharma Group Ltd Competitors by Total Assets
Key competitors of Mayne Pharma Group Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$55.91 Million |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$7.84 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥233.15 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥83.17 Billion |
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥112.28 Billion |
Mayne Pharma Group Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.47 | 2.24 |
| Quick Ratio | 1.16 | 1.23 | 1.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$91.78 Million | AU$146.66 Million | AU$271.69 Million |
Mayne Pharma Group Ltd - Advanced Valuation Insights
This section examines the relationship between Mayne Pharma Group Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.58 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | AU$1.01 Billion |
| Market Capitalization | $159.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mayne Pharma Group Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mayne Pharma Group Ltd's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mayne Pharma Group Ltd (2006–2025)
The table below shows the annual total assets of Mayne Pharma Group Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.01 Billion ≈ $717.90 Million |
-11.25% |
| 2024-06-30 | AU$1.14 Billion ≈ $808.87 Million |
-8.35% |
| 2023-06-30 | AU$1.25 Billion ≈ $882.58 Million |
-3.15% |
| 2022-06-30 | AU$1.29 Billion ≈ $911.29 Million |
-11.98% |
| 2021-06-30 | AU$1.46 Billion ≈ $1.04 Billion |
-19.83% |
| 2020-06-30 | AU$1.83 Billion ≈ $1.29 Billion |
+11.54% |
| 2019-06-30 | AU$1.64 Billion ≈ $1.16 Billion |
-10.61% |
| 2018-06-30 | AU$1.83 Billion ≈ $1.30 Billion |
-4.41% |
| 2017-06-30 | AU$1.91 Billion ≈ $1.35 Billion |
+22.96% |
| 2016-06-30 | AU$1.56 Billion ≈ $1.10 Billion |
+194.43% |
| 2015-06-30 | AU$528.95 Million ≈ $374.26 Million |
+98.99% |
| 2014-06-30 | AU$265.82 Million ≈ $188.08 Million |
+13.89% |
| 2013-06-30 | AU$233.39 Million ≈ $165.14 Million |
+332.74% |
| 2012-06-30 | AU$53.93 Million ≈ $38.16 Million |
+0.48% |
| 2011-06-30 | AU$53.68 Million ≈ $37.98 Million |
-24.56% |
| 2010-06-30 | AU$71.15 Million ≈ $50.34 Million |
+785.41% |
| 2009-06-30 | AU$8.04 Million ≈ $5.69 Million |
-31.28% |
| 2008-06-30 | AU$11.69 Million ≈ $8.27 Million |
-24.61% |
| 2007-06-30 | AU$15.51 Million ≈ $10.97 Million |
+53384.34% |
| 2006-06-30 | AU$29.00K ≈ $20.52K |
-- |
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more